Sensitivity to brentuximab vedotin depends on CD30-expression levels in different subtypes of cutaneous T-cell lymphoma cell lines

被引：0
|
作者：
Hofer, V. [1 ]
Wobser, M. [1 ]
Maurus, K. [2 ]
Houben, R. [1 ]
Schrama, D. [1 ]
机构：
[1] Uniklinikum Wurzburg, Wurzburg, Germany
[2] Univ Wurzburg, Pathol, Wurzburg, Germany
来源：
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2023年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
eP105
引用
收藏
页码：92 / 92
页数：1
相关论文
共 50 条
  • [31] Brentuximab vedotin in the treatment of cutaneous T-cell lymphomas: data from the Spanish Primary Cutaneous Lymphoma Registry
    Muniesa, C.
    Gallardo, F.
    Garcia-Doval, I.
    Estrach, M. T.
    Combalia, A.
    Morillo-Andujar, M.
    De la Cruz Vicente, F.
    Machan, S.
    Moya-Martinez, C.
    Rovira, R.
    Sanchez-Gonzalez, B.
    Acebo, E.
    Amutio, E.
    Penate, Y.
    Losada-Castillo, M. C.
    Garcia-Muret, M. P.
    Iznardo, H.
    Roman-Curto, C.
    Canueto, J.
    Fernandez de Misa, R.
    Florez, A.
    Izu, R.
    Torres-Navarro, I.
    Zayas, A.
    Perez-Paredes, G.
    Blanes, M.
    Yanguas, J. I.
    Perez-Ferriols, A.
    Callejas-Charavia, M.
    Ortiz-Romero, Pl
    Perez-Gil, A.
    Prieto-Torres, L.
    Gonzalez-Barca, E.
    Servitje, O.
    EUROPEAN JOURNAL OF CANCER, 2022, 173 : S40 - S41
  • [32] Trial in Progress: A Phase 4 Multicenter Study of Brentuximab Vedotin Treatment in Chinese Patients with CD30Positive Cutaneous T-Cell Lymphoma
    Wang, Qian
    Jiang, Ming
    Zhang, Chunlei
    Wu, Sheng
    Jiang, Wenhan
    Ji, Meng
    Chen, Tong
    BLOOD, 2022, 140 : 12044 - 12045
  • [33] Brentuximab vedotin - a highly potent Therapy in cutaneous T-Cell-Lymphoma
    Pax, A. T.
    Stadler, R.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2014, 12 : 2 - 2
  • [34] CD30+ leukemic cutaneous T-cell lymphoma
    Ellis, Ariana
    Christensen, Luisa F.
    Sharma, Timmie
    Meyerson, Howard
    Kord, Honda
    Cooper, Kevin D.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 84 (02) : 530 - 532
  • [35] Clinical Experience With Brentuximab Vedotin in Treating Cutaneous T-Cell Lymphoma: A Retrospective Review From China
    Pang, Zhiyu
    Zhang, Shan
    Liu, Zhaorui
    Zhang, Wei
    Liu, Jie
    DERMATOLOGIC THERAPY, 2024, 2024
  • [36] Real-world evidence study of brentuximab vedotin retreatment in patients with cutaneous T-cell lymphoma
    Mitteldorf, C.
    de Masson, A.
    Beylot-Barry, M.
    Wobster, M.
    Zomas, A.
    Stache, V.
    Assaf, C.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S77 - S78
  • [37] Primary cutaneous peripheral T-cell lymphoma not otherwise specified (NOS) and successful use of brentuximab vedotin
    Makris, Nikolaos
    Finck, Stefanie
    Kirchner, Kathrin
    von den Driesch, Peter
    AKTUELLE DERMATOLOGIE, 2023, 49 (06) : 265 - 267
  • [38] Brentuximab vedotin as second-line treatment for primary cutaneous CD8+aggressive epidermotropic T-cell lymphoma
    Calvao, J.
    Santiago, L.
    Afonso, C.
    Cardoso, J. C.
    Coutinho, I.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S67 - S67
  • [39] A Successful Experience with Brentuximab Vedotin in Relapsing/Refractory Cutaneous T-Cell Lymphoma: Two Case Reports
    Gorenkova, Liliya
    Kravchenko, Sergey K.
    Kovrigina, Alla M.
    Savchenko, Valery G.
    BLOOD, 2018, 132
  • [40] Successful Therapy with Brentuximab Vedotin at clinic-adapted Delivery Intervals in primary cutaneous, CD30-positive, large-cell, anaplastic T-cell Lymphoma
    Bley, L. I.
    Schulze, H. J.
    Grundmann, S.
    Weishaupt, C.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2019, 17 : 45 - 45
12345